BENITIONSClinical Trial Intelligence

A Study of Soticlestat in Adults and Children With Rare Epilepsies

2상 조기 종료 NCT03635073

대상 질환Epilepsy, Dravet Syndrome, Lennox-Gastaut Syndrome
임상 단계2상
스폰서Takeda
상태조기 종료
참여자 수156 명
중재(약물)Soticlestat
시작일2018년 7월 19일
완료일2025년 7월 30일
결과 공개일2026년 3월 19일

요약

The main aim is to assess the long-term safety and tolerability of soticlestat when used along with other anti-seizure treatment. Participants will receive soticlestat twice a day. Participants will visit the study clinic every 2-6 months throughout the study. Study treatments may continue as long as the participant is receiving benefit from it.

Percentage of Participants Who Experienced At Least One Treatment-emergent Adverse Event (AE)

From screening up to end of the study (up to approximately 84 months) · percentage of participants

Soticlestat91.0 percentage of participants

Change From Baseline in Behavioral and Adaptive Functional Measures Using the Vineland Adaptive Behavior Scale (VABS)

Baseline, Week 338 · score on a scale

Soticlestat32.3 ± 21.64 score on a scale
Soticlestat0.7 ± 0.58 score on a scale
Soticlestat33.5 ± 29.19 score on a scale
Soticlestat-3.0 ± 2.83 score on a scale
Soticlestat12.3 ± 15.89 score on a scale
Soticlestat-5.5 ± 2.12 score on a scale

Change From Baseline in Behavior Measures Using Total Scores of the Aberrant Behavior Checklist-Community Edition (ABC-C) for Participants Greater Than Equal to (≥) 6 Years of Age

Baseline, Week 338 · score on a scale

Soticlestat36.8 ± 26.11 score on a scale
Soticlestat-16.3 ± 8.50 score on a scale

BENITIONS에서 보기 ClinicalTrials.gov 원문 보기

같은 질환의 다른 임상

전체 임상

이 페이지는 ClinicalTrials.gov의 공개 데이터를 정리한 것입니다. 의학적 조언이 아니며 투자 권유나 자문도 아닙니다. 반드시 전문의와 상담하세요.